NOUS-209
nouscom
['solid tumor', 'nouscom']
nouscom announces positive full phase 1 data of nous-209, an 'off-the-shelf' neoantigen cancer immunotherapy for the treatment of dmmr/msi-h solid tumors, at asco 2022 
World News Guru is completely free and offers a broad range of media content from a varied and extensive range of sources.